Dimensional Fund Advisors LP boosted its holdings in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) by 204.9% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,868,968 shares of the biopharmaceutical company’s stock after acquiring an additional 1,255,962 shares during the quarter. Dimensional Fund Advisors LP owned 1.37% of Achillion Pharmaceuticals worth $8,579,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Cambridge Investment Research Advisors Inc. increased its position in Achillion Pharmaceuticals by 3.6% in the 2nd quarter. Cambridge Investment Research Advisors Inc. now owns 23,130 shares of the biopharmaceutical company’s stock valued at $106,000 after acquiring an additional 800 shares during the period. SG Americas Securities LLC increased its position in Achillion Pharmaceuticals by 18.6% in the 2nd quarter. SG Americas Securities LLC now owns 26,429 shares of the biopharmaceutical company’s stock valued at $121,000 after acquiring an additional 4,144 shares during the period. TradeLink Capital LLC acquired a new stake in Achillion Pharmaceuticals in the 2nd quarter valued at approximately $132,000. Legal & General Group Plc increased its position in Achillion Pharmaceuticals by 53.8% in the 2nd quarter. Legal & General Group Plc now owns 42,900 shares of the biopharmaceutical company’s stock valued at $196,000 after acquiring an additional 15,000 shares during the period. Finally, UBS Asset Management Americas Inc. increased its position in Achillion Pharmaceuticals by 83.8% in the 1st quarter. UBS Asset Management Americas Inc. now owns 53,669 shares of the biopharmaceutical company’s stock valued at $226,000 after acquiring an additional 24,471 shares during the period. Hedge funds and other institutional investors own 74.81% of the company’s stock.

WARNING: This piece was first published by Daily Political and is owned by of Daily Political. If you are accessing this piece on another domain, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this piece can be viewed at https://www.dailypolitical.com/2017/11/19/dimensional-fund-advisors-lp-has-8-58-million-position-in-achillion-pharmaceuticals-inc-achn.html.

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) opened at $3.43 on Friday. Achillion Pharmaceuticals, Inc. has a 1 year low of $2.95 and a 1 year high of $5.66.

Achillion Pharmaceuticals (NASDAQ:ACHN) last issued its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.18) by $0.04. During the same period last year, the firm earned ($0.15) earnings per share. analysts forecast that Achillion Pharmaceuticals, Inc. will post -0.63 EPS for the current year.

Several equities analysts have recently issued reports on the company. Zacks Investment Research upgraded Achillion Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.25 price target on the stock in a research report on Monday, November 13th. Robert W. Baird cut Achillion Pharmaceuticals from an “outperform” rating to a “neutral” rating and set a $5.00 price target on the stock. in a research report on Thursday, August 10th. Maxim Group set a $7.00 price target on Achillion Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, August 9th. BidaskClub upgraded Achillion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Wednesday, August 16th. Finally, Chardan Capital lowered their price target on Achillion Pharmaceuticals from $5.00 to $4.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 9th. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $5.29.

Achillion Pharmaceuticals Company Profile

Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.

Institutional Ownership by Quarter for Achillion Pharmaceuticals (NASDAQ:ACHN)

Receive News & Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.